VAXON-BIOTECH ANNOUNCES RESULTS OF IMMUNOTHERAPY STUDY

Vaxon-Biotech has announced the preliminary results of a Phase I trial of its candidate vaccine Vx-001. Based on observations in 27 newly included cancer patients (current total 46 patients), Vx-001 continues to show clinical benefits and to be well-tolerated.

This clinical trial involved 19 patients with advanced-stage metastatic cancers of different types which had progressed despite chemotherapy. Fourteen patients completed the study. This treatment induced lengthy disease stabilization in four patients, for periods of 36 weeks to 94 weeks. A specific and functional anti-Vx-001 immune response was detected in more than 95 percent of the patients who were evaluated. Overall, treatment with Vx-001 was well-tolerated, with no significant adverse effects and no evidence of autoimmunity.